Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pegfilgrastim
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 113 for your search:
Start Over
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: AMLSG07-04, NCT00151242
Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel
Phase: Phase III, Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NEUGR-002, NCT00837265
GCPGC in Chemotherapy-induced Neutropenia
Phase: Phase III, Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GCPGC P2/3, NCT01328938
Phase III Pilot Randomized Study of Filgrastim-SD/01 Versus Filgrastim (G-CSF) With Concurrent Chemotherapy in Patients With Newly Diagnosed Sarcoma (Closed to Accrual as of 5/26/2009)
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 25 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-00-C-0092, AMGEN-20000124, NCT00020137
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: GOG-0184, NCI-2012-02350, ECOG-G0184, RTOG-EN0130, CDR0000068020, U10CA027469, NCT00006011
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 60
Sponsor: Other
Protocol IDs: EORTC-20012, GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, 2004-001558-10, hd8, NCT00049595
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: EORTC-62012, NCT00061984
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000334899, S0221, U10CA032102, SWOG-S0221, NCT00070564
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery
Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000463447, ICR-TACT2, EU-205114, EUDRACT-2004-000066-13, MREC-04/MRE00/88, ISRCTN68068041, NCT00301925
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: IIL-DLCL04, EudraCT number 2007-000275-42, NCT00499018
Phase III Randomized Pilot Study of Adjuvant Chemotherapy Comprising Doxorubicin Hydrochloride or Epirubicin Hydrochloride and Cyclophosphamide in Older Women With Invasive Breast Carcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Unknown
Age: 70 and over
Sponsor: Other
Protocol IDs: UKM-CCH-ACTION, ICR-CTSU/2006/10004-ACTION, EU-20751, EUDRACT-2005-005721, ISRCTN41708421, BIG-205, BIG 2-05, NCT00516425
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: NSABP B-46-I, USOR 07132, NCT00887536
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080259, NCT00911170
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-01738, CDR0000659024, GOG-0250, U10CA027469, NCT01012297
Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NEUGR-003, NCT01126190
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LA-EP06-302, NCT01516736
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: HHPG-19K -III-01, NCT01611051
Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: DA3031_NP_III, NCT01674855
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LA-EP06-301, 2011-004532-58, NCT01735175
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: MA22, CAN-NCIC-MA22, CDR0000316237, NCT00066443
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02600, 12975A, N01CM62201, CDR0000371904, UCCRC-12975A, 6243, NCI-6243, NCT00086944
Start Over